News
BTAI
1.060
+3.88%
0.040
Weekly Report: what happened at BTAI last week (0406-0410)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Bioxcel Therapeutics (BTAI)
TipRanks · 4d ago
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PR Newswire · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
Reuters · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
Reuters · 6d ago
BioXcel Therapeutics Begins Enrollment In DoW-Funded Study Of BXCL501 For Acute Stress Reactions
NASDAQ · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Delta, GATX, Humana
Reuters · 6d ago
BUZZ-BioXcel rises as trial starts for its stress disorder drug in trauma victims
Reuters · 6d ago
BioXcel Therapeutics enrolls first patients in BXCL501 trial
TipRanks · 6d ago
BioXcel enrolls first patients in DoW-funded Phase 2a BXCL501 acute stress trial
Reuters · 6d ago
BIOXCEL THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENTS IN U.S. DEPARTMENT OF WAR-FUNDED STUDY OF BXCL501 (SUBLINGUAL DEXMEDETOMIDINE) FOR TREATMENT OF ACUTE STRESS REACTIONS
Reuters · 6d ago
Weekly Report: what happened at BTAI last week (0330-0403)?
Weekly Report · 04/06 09:32
BioXcel Therapeutics Price Target Cut to $5.00/Share From $6.00 by HC Wainwright & Co.
Dow Jones · 04/02 10:48
HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5
Benzinga · 04/02 10:37
BioXcel Therapeutics: Undervalued Franchise with IGALMI PDUFA Catalyst Supports Buy Rating Despite Reduced Target
TipRanks · 04/02 10:15
BioXcel Therapeutics price target lowered to $5 from $6 at H.C. Wainwright
TipRanks · 04/02 10:12
FDA Accepts BioXcel sNDA for At-Home IGALMI Use
TipRanks · 04/01 12:49
BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA
TipRanks · 04/01 11:09
The FDA Accepts Its Bioxcel Therapeutics' Supplemental New Drug Application For Igalmi For At-home Use In The Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia, PDUFA Date Of November 14
Benzinga · 04/01 11:04
BIOXCEL THERAPEUTICS INC - FDA ASSIGNS PDUFA TARGET ACTION DATE OF NOV 14, 2026 FOR IGALMI SNDA
Reuters · 04/01 11:00
More
Webull provides a variety of real-time BTAI stock news. You can receive the latest news about Bioxcel Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.